TrialClinical cardiology2012

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy.

Payal Kohli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.